SRPT241129C120000
- 13.60
- -1.50-9.93%
Sarepta Therapeutics Newsroom
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Express News | Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Sarepta Therapeutics Stock Surges 43% YTD: How to Play the Stock?
US MOVERS&SHAKERS Nov 25-Nov 29, 2024
Sarepta Price Target Lowered to $202 From $205 at Needham
A Quick Look at Today's Ratings for Sarepta Therapeutics(SRPT.US), With a Forecast Between $182 to $215
RBC Capital Remains a Buy on Sarepta Therapeutics (SRPT)
Short Stock Ideas From Each Sector With Earnings Quality in the Bottom 20%
Sarepta Therapeutics Is Maintained at Overweight by Piper Sandler
SRPT Inks $11B Licensing Deal With Arrowhead for Rare Gene Therapies
Wall Street Analysts Think Sarepta Therapeutics (SRPT) Could Surge 42.11%: Read This Before Placing a Bet
A Quick Look at Today's Ratings for Sarepta Therapeutics(SRPT.US), With a Forecast Between $182 to $217
Sarepta Therapeutics (SRPT) Gets a Buy From TD Cowen
Sarepta Therapeutics Receives Buy Rating From Gil Blum: Strategic Partnerships and Financial Stability Highlight Growth Potential
Express News | Needham Maintains Buy on Sarepta Therapeutics, Lowers Price Target to $202
Sarepta Therapeutics Analyst Ratings
Sarepta Therapeutics: Strategic Expansion and Robust Pipeline Justify Buy Rating and $217 Price Target
Express News | Sarepta Therapeutics Inc : Piper Sandler Cuts Target Price to $182 From $200
Wolfe's Most Shorted 'Hit List' – FSLR, BE, WBA, SJM
Trending Stocks Today | CIMG Soars 138.09%